Acorda Therapeutics Inc. (ACOR)

10.76
0.26 2.36
NASDAQ : Health Technology
Prev Close 11.02
Open 10.93
Day Low/High 10.68 / 11.02
52 Wk Low/High 9.58 / 36.35
Volume 649.76K
Avg Volume 912.70K
Exchange NASDAQ
Shares Outstanding 48.13M
Market Cap 554.94M
EPS 0.70
P/E Ratio N/A
Div & Yield N.A. (N.A)
Acorda To Present At The Stifel 2017 Healthcare Conference

Acorda To Present At The Stifel 2017 Healthcare Conference

Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced that Ron Cohen, M.

Geron Shares Rise on Fast Track Designation -- Biotech Movers

Geron Shares Rise on Fast Track Designation -- Biotech Movers

The FDA granted fast track designation to imetelstat as a potential treatment for adults with with transfusion-dependent anemia.

Acorda Provides Financial And Pipeline Update For Third Quarter 2017

Acorda Provides Financial And Pipeline Update For Third Quarter 2017

Acorda Therapeutics, Inc. (Nasdaq: ACOR) provided a financial and pipeline update for the third quarter ended September 30, 2017.

Short Interest In Acorda Therapeutics Drops 12.7%

Short Interest In Acorda Therapeutics Drops 12.7%

The most recent short interest data has been released for the 10/13/2017 settlement date, which shows a 799,313 share decrease in total short interest for Acorda Therapeutics Inc , to 5,496,213, a decrease of 12.70% since 09/29/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Acorda Therapeutics Reaches Analyst Target Price

Acorda Therapeutics Reaches Analyst Target Price

In recent trading, shares of Acorda Therapeutics Inc have crossed above the average analyst 12-month target price of $26.75, changing hands for $27.20/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Acorda Third Quarter 2017 Update: Webcast/Conference Call Scheduled For October 31, 2017

Acorda Third Quarter 2017 Update: Webcast/Conference Call Scheduled For October 31, 2017

Acorda Therapeutics, Inc. (Nasdaq:ACOR) will host a conference call and webcast to report its third quarter 2017 financial results and pipeline updates on Tuesday, October 31 at 8:30 a.

Acorda Therapeutics Stock Sees Short Interest Move 12.6% Higher

Acorda Therapeutics Stock Sees Short Interest Move 12.6% Higher

The most recent short interest data has been released for the 09/15/2017 settlement date, which shows a 916,853 share increase in total short interest for Acorda Therapeutics Inc , to 8,222,790, an increase of 12.55% since 08/31/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

ACOR Crosses Above Average Analyst Target

ACOR Crosses Above Average Analyst Target

In recent trading, shares of Acorda Therapeutics Inc have crossed above the average analyst 12-month target price of $23.29, changing hands for $23.35/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Acorda To Present At The Cantor Fitzgerald Global Healthcare Conference

Acorda To Present At The Cantor Fitzgerald Global Healthcare Conference

Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced that Ron Cohen, M.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ACOR,GPS,MSB,PNNT,STFC,USG,VCO Downgrades: EXEL,JCI,NCS,PEIX Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

INVESTOR ALERT: Goldberg Law PC Announces An Investigation Of Acorda Therapeutics, Inc.

INVESTOR ALERT: Goldberg Law PC Announces An Investigation Of Acorda Therapeutics, Inc.

Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Acorda Therapeutics, Inc.

ACORDA THERAPEUTICS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In Acorda Therapeutics, Inc. To Contact The Firm

ACORDA THERAPEUTICS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In Acorda Therapeutics, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Acorda Therapeutics, Inc.

Acorda Adopts Shareholder Rights Plan

Acorda Adopts Shareholder Rights Plan

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that its Board of Directors has adopted a Shareholder Rights Plan, effective September 1, 2017, and declared a dividend distribution of one preferred share purchase...

Acorda Therapeutics, Inc. Investor Alert: Legal Investigation For Potential Securities Law Violations

Acorda Therapeutics, Inc. Investor Alert: Legal Investigation For Potential Securities Law Violations

Girard Gibbs LLP is investigating claims on behalf of investors of Acorda Therapeutics, Inc.

ACORDA THERAPEUTICS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In Acorda Therapeutics, Inc. To Contact The Firm

ACORDA THERAPEUTICS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In Acorda Therapeutics, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Acorda Therapeutics, Inc.

INVESTOR ALERT: Investigation Of Acorda Therapeutics Announced By Holzer & Holzer

INVESTOR ALERT: Investigation Of Acorda Therapeutics Announced By Holzer & Holzer

Holzer & Holzer, LLC is investigating whether Acorda Therapeutics, Inc.

Acorda Shares Down on FDA's 'Refusal to File' Letter - Biotech Movers

Acorda Shares Down on FDA's 'Refusal to File' Letter - Biotech Movers

The firm received a "refusal to file letter" from the FDA regarding the new drug application for Inbrija, a potential treatment for Parkinson's disease.

Acorda Receives Refusal To File Letter From FDA For INBRIJA™ (CVT-301, Levodopa Inhalation Powder) New Drug Application

Acorda Receives Refusal To File Letter From FDA For INBRIJA™ (CVT-301, Levodopa Inhalation Powder) New Drug Application

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it received a Refusal to File (RTF) letter from the U.

Acorda Stiff-Arms Investor's Demand for Sale

Acorda Stiff-Arms Investor's Demand for Sale

Scopia said losing a legal battle over patents was a watershed moment for Acorda that demands a new strategy.

Acorda Provides Financial And Pipeline Update For Second Quarter 2017

Acorda Provides Financial And Pipeline Update For Second Quarter 2017

Acorda Therapeutics, Inc. (Nasdaq: ACOR) provided a financial and pipeline update for the second quarter ended June 30, 2017.

September 15th Options Now Available For Acorda Therapeutics (ACOR)

September 15th Options Now Available For Acorda Therapeutics (ACOR)

Investors in Acorda Therapeutics Inc saw new options begin trading today, for the September 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACOR options chain for the new September 15th contracts and identified one put and one call contract of particular interest.

These Are the Best Growth Stocks Right Now in Biotech

These Are the Best Growth Stocks Right Now in Biotech

Top names.

Short Interest Makes 16% Move For ACOR

Short Interest Makes 16% Move For ACOR

The most recent short interest data has been released for the 06/30/2017 settlement date, which shows a 1,046,512 share increase in total short interest for Acorda Therapeutics Inc , to 7,545,998, an increase of 16.10% since 06/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Acorda Second Quarter 2017 Update Webcast/Conference Call Scheduled For July 27, 2017

Acorda Second Quarter 2017 Update Webcast/Conference Call Scheduled For July 27, 2017

Acorda Therapeutics, Inc. (Nasdaq:ACOR) will host a conference call and webcast to review its second quarter 2017 financial results and pipeline updates on Thursday, July 27 at 8:30 a.

Acorda Submits New Drug Application To U.S. Food And Drug Administration For INBRIJATM (CVT-301, Levodopa Inhalation Powder)

Acorda Submits New Drug Application To U.S. Food And Drug Administration For INBRIJATM (CVT-301, Levodopa Inhalation Powder)

Acorda Therapeutics, Inc. (NASDAQ: ACOR) has submitted a New Drug Application (NDA) to the U.

Biotech Insider Just Loaded Up $234 Million Worth the Stock

Biotech Insider Just Loaded Up $234 Million Worth the Stock

Massive biotech bet!

Biotech Movers: Adamis Shares Jump After FDA Approves Epinephrine Pre-filled Syringe

Biotech Movers: Adamis Shares Jump After FDA Approves Epinephrine Pre-filled Syringe

Adamis Pharmaceuticals, Impax Laboratories and Accorda Therapeutics were among the biotech stock movers in premarket trading on June 16.

Biotech Movers: Albany Molecular Shares Soar on Sale to PE Firms

Biotech Movers: Albany Molecular Shares Soar on Sale to PE Firms

Albany Molecular Research, Acorda Therapeutics and PTC Therapeutics were among the biotech stock movers in premarket trading on Tuesday.

Acorda Presenting New Tozadenant Data At 2017 MDS Congress

Acorda Therapeutics, Inc. (Nasdaq: ACOR) is presenting new data from clinical and preclinical studies of tozadenant at the 2017 International Congress of Parkinson's Disease and Movement Disorders (MDS), being held in...

TheStreet Quant Rating: D (Sell)